(MNMD) Mind Medicine - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: CA60255C8850
MNMD: Medicines, Treatments, Therapies, Drugs, Pills, Remedies
Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company, specializes in developing innovative treatments for brain health disorders. The companys pipeline includes MM-120, a lysergic acid diethylamide (LSD) derivative, currently in Phase 2 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Additionally, MM-402, the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), is in Phase 1 clinical trials for treating core symptoms of autism spectrum disorder (ASD). MindMed is headquartered in New York, New York.
Stock Details: Ticker Symbol: MNMD | Exchange: NASDAQ | Type: Common Stock | Country Origin: United States | GICS Sub Industry: Biotechnology.
3-Month Forecast: Based on the provided data, MNMDs average volume over 20 days is 3,231,788 shares. The stock is currently trading at $6.70, below its 20-day SMA of $7.98 and 50-day SMA of $7.47. The 200-day SMA is $7.22, indicating a potential downtrend. The ATR of 0.76 suggests moderate volatility. Fundamentally, the company has a market cap of $494.99M USD, a P/B ratio of 2.01, and an RoE of -37.30%, reflecting significant R&D investments without current profits.
Additional Sources for MNMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MNMD Stock Overview
| Market Cap in USD | 485m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2020-03-03 |
MNMD Stock Ratings
| Growth 5y | 0.15% |
| Fundamental | -43.0% |
| Dividend | 0.0% |
| Rel. Strength Industry | -15.6 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 4.94 USD |
| Fair Price DCF | - |
MNMD Dividends
No Dividends PaidMNMD Growth Ratios
| Growth Correlation 3m | -25.6% |
| Growth Correlation 12m | -49.4% |
| Growth Correlation 5y | -41% |
| CAGR 5y | 13.96% |
| CAGR/Max DD 5y | 0.14 |
| Sharpe Ratio 12m | -1.15 |
| Alpha | -38.00 |
| Beta | 1.82 |
| Volatility | 78.29% |
| Current Volume | 895k |
| Average Volume 20d | 1734k |
As of March 15, 2025, the stock is trading at USD 6.35 with a total of 895,018 shares traded.
Over the past week, the price has changed by -7.03%, over one month by -35.79%, over three months by -14.19% and over the past year by -21.99%.
Probably not. Based on ValueRay Fundamental Analyses, Mind Medicine (NASDAQ:MNMD) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -42.97 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MNMD as of March 2025 is 4.94. This means that MNMD is currently overvalued and has a potential downside of -22.2%.
Mind Medicine has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy MNMD.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, MNMD Mind Medicine will be worth about 5.9 in March 2026. The stock is currently trading at 6.35. This means that the stock has a potential downside of -7.24%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 25.6 | 303.1% |
| Analysts Target Price | 8 | 26% |
| ValueRay Target Price | 5.9 | -7.2% |